Trials / Conditions / Recurrent Gallbladder Cancer

Recurrent Gallbladder Cancer

15 registered clinical trials studyying Recurrent Gallbladder Cancer.

Status	Trial	Sponsor	Phase
Terminated	Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers NCT01229111	National Cancer Institute (NCI)	Phase 2
Terminated	Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer Th NCT00478140	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec NCT00397384	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors NCT00356889	National Cancer Institute (NCI)	Phase 2
Completed	S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma NCT00238212	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer NCT00107536	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot B NCT00101036	National Cancer Institute (NCI)	Phase 2
Terminated	EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191	National Cancer Institute (NCI)	N/A
Terminated	Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Du NCT00085410	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer NCT00033462	National Cancer Institute (NCI)	Phase 2
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Completed	Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496	National Cancer Institute (NCI)	Phase 1
Terminated	BMS-247550 in Treating Patients With Liver or Gallbladder Cancer NCT00023946	National Cancer Institute (NCI)	Phase 2
Completed	Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074	National Cancer Institute (NCI)	Phase 1
Withdrawn	Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating NCT00253617	Jonsson Comprehensive Cancer Center	Phase 3